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BACKGROUND: There is a need to identify effective
practical interventions to decrease cardiovascular dis-
ease risk in patients with diabetes.
OBJECTIVE: We examine the impact of participation in
a collaborative implementing the chronic care model
(CCM) on the reduction of cardiovascular disease risk in
patients with diabetes.
DESIGN: Controlled pre- and postintervention study.
PATIENTS/PARTICIPANTS: Persons with diabetes re-
ceiving care at 13 health care organizations exposed to
the CCM collaborative and controls receiving care in
nonexposed sites.
MEASUREMENTS AND MAIN RESULTS: Ten-year risk
of cardiovascular disease; determined using a modified
United Kingdom Prospective Diabetes Study risk engine
score. A total number of 613 patients from CCM
intervention sites and 557 patients from usual care
control sites met the inclusion criteria. The baseline
mean 10-year risk of cardiovascular disease was 31%
for both the intervention group and the control group.
Participants in both groups had improved blood pres-
sure, lipid levels, and HbA1c levels during the observa-
tion period. Random intercept hierarchical regression
models showed that the intervention group had a 2.1%
(95% CI −3.7%, −0.5%) greater reduction in predicted
risk for future cardiovascular events when compared to
the control group. This would result in a reduced risk of
one cardiovascular disease event for every 48 patients
exposed to the intervention.
CONCLUSIONS: Over a 1-year interval, this collabora-
tive intervention using the CCM lowered the cardiovas-
cular disease risk factors of patients with diabetes who
were cared for in the participating organization’s set-
tings. Further work could enhance the impact of this
promising multifactorial intervention on cardiovascular
disease risk reduction.
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P
ersons with type-2 diabetes mellitus have a two- to
fourfold increased risk of myocardial infarction and
sudden death compared to persons without diabetes, and
cardiovascular disease accounts for roughly half of all deaths
in people with diabetes.
1–5 Efficacious therapies for the treat-
ment of patients with diabetes have long been available,
6–10 and
evidence from randomized controlled trials shows that intensive
use of these therapies can reduce the burden of disease.
9,11–16
However, less is known about how to translate these clinical research
findings into real-world practice.
17 A metaanalysis examining
interventions to improve care for patients with diabetes found
that studies rarely assessed the impact on patient outcomes.
18
Translating proven therapies and interventions into routine
practice and measuring change in population level health is
not easy.
19 The chronic care model (CCM) is a framework for
managing chronic illness, which facilitates planning and
coordination among providers while helping patients to play
an informed role in managing their own care.
20,21 The
components of the CCM have been shown to be effective for
improving certain process measures.
18,22–24 Less is known
about implementing the model as a whole and its impact on
long-term cardiovascular disease risk factors.
25
A collaborative intervention is a method used to help health
care organizations apply continuous quality improvement tech-
niques and affect organizational change.
26 Collaborative interven-
tions, also termed as Breakthrough Series, have been conducted
for hundreds of teams addressing multiple clinical condi-
tions.
26,27 However, there have been few controlled trials evaluat-
ing the effectiveness of these interventions.
23,25,27–29 In light of
this, we conducted a multicenter evaluation of a collaborative
intervention to implement the CCM for diabetes care. We ask: Is
exposure to a CCM collaborative intervention associated with
improved cardiovascular disease risk for patients with diabetes?
METHODS
Overview
We examine the impact of a CCM-based diabetes care collab-
orative on the 10-year risk of cardiovascular disease, defined
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215as fatal and nonfatal myocardial infarction or sudden death, in
patients with diabetes cared for at clinical sites where collab-
orative induced changes were implemented compared to
patients at control sites within the same organization receiving
the usual care.
Intervention
The intervention is a series of 3 learning sessions and a final
meeting designed to help organizations implement the CCM for
diabetes care. The first collaborative in 1999 was run by the
Institute for Healthcare Improvement (IHI) and had partici-
pants from the Eastern, Western, and Southern regions of the
United States, whereas the second in 2001 was limited to
organizations from the State of Washington. Organizations in
the first collaborative paid a flat fee of $12,000 to participate,
whereas the second collaborative (run by Qualis, the Washing-
ton State Quality Improvement Organization and the Washing-
ton State Department of Health) cost $200 per attendee per
session. Over the course of a year, participating organizations
had an average of 8 members on a team with generally at least
1 physician participant. They were taught methods for making
system level organizational change, the elements of the CCM,
and evidence-based diabetes clinical care measures and ther-
apies. Experts in diabetes disease management and quality
improvement guided the teams to study, test, and implement
improvements in essential care processes for diabetes in their
intervention sites (Fig. 1). The 13 intervention sites made an
average of 45 changes (SD=18) during the study period. In
delivery system redesign, most sites worked on enhancing care
management roles, providing proactive follow-up, planning
visits, and improving the visit system. All sites implemented
patienteducation, andthe majority alsoprovided resourcesand
tools to patients and worked with patients in care planning.
Figure 1. Chronic illness care collaborative intervention. Adapted from Cretin et al. 2004.
31
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attention from almost all sites. A more detailed description of
the changes can be found elsewhere.
30
Study Design and Setting
Our study was a pre- and postevaluation of participants cared
for at intervention and control sites. Representatives from 40
health care organizations volunteered to participate in one of
the two CCM collaboratives. We contacted health care “organi-
zations” with administrative oversight over multiple clinical
“sites” for our evaluation. This enabled us to obtain control sites
(other clinic or practice) of similar size, location, and financial
type as the intervention site with similar patients from within
the same organization. Of the original 40, 3 organizations
dropped out of the collaborative and 20 were too small to
provide within organization control sites, leaving 17 of whom 13
agreedtoparticipate andfurnishcontrolsites.Theparticipating
organizations cared for patients in nonprofit clinics, a nonprofit
health plan, for-profit physician groups, and veteran’s admin-
istration facilities. Expanded descriptions of the design, partic-
ipating organizations, and selection of control groups can be
found in the overall study’s technical appendix http://www.
rand.org/publications/WR/WR269/, and a detailed review of
the collaborative intervention and our evaluation methods can
be found in Cretin et al.
31
Outcome
We analyzed the impact of the intervention on change in the
10-year predicted risk of cardiovascular disease as determined
by the United Kingdom Prospective Diabetes Study (UKPDS)
risk engine (Isis Innovation Ltd 2001© Headington, Oxford,
UK) for the study population as a whole and for high-risk and
low-risk patients. The risk of getting heart disease in the next
Table 1. Baseline Characteristics*
Intervention
(n=613)
Control
(n=557)
P-value for two-
sample t test
Percent male 64% (48%) 59%
(49%)
0.09
Mean age in years 64 (12) 65 (11) 0.54
White 87% (33%) 91%
(29%)
0.09
African American 5% (22%) 4% (19%) 0.21
Hispanic 2% (12%) 1% (12%) 0.91
At least high school
education
42% (49%) 47%
(50%)
0.07
Income less
than $30,000
41% (49%) 46%
(50%)
0.23
Insured 91% (28%) 93%
(26%)
0.42
Health maintenance
organization
32% (47%) 26%
(44%)
0.04
Smoker 55% (50%) 58%
(49%)
0.28
Duration diabetes in
years
7.7 (7.5) 8.2 (8.2) 0.26
Comorbidity
Weighted Score
0.943 (97) 0.962 (96) 0.73
Mean systolic blood
pressure (mmHg)
138 (16) 139 (14) 0.33
Total chol/HDL
ratio
†
4.6 (1.4) 4.7 (1.5) 0.08
Mean LDL
cholesterol
111 (41) 115 (38) 0.14
Mean HbA1c
†† 7.9 (1.8) 7.7 (1.6) 0.02
UKPDS 10-year risk
score
30.7%
(21%)
31.0%
(21%)
0.86
*Characteristics shown above are based on comparisons including
imputed data. Standard deviation is noted in parentheses.
†Log total chol/HDL is the log of the ratio of total serum cholesterol
divided by the high-density lipoprotein level.
††HbA1c is the glycosylated hemoglobin.
Table 2. Unadjusted Difference in Differences for Outcomes
Intervention Preperiod
Mean
Intervention Pre–post
Change
Control Preperiod
Mean
Control Pre–post
Change
Difference in
Differences
Observations 613 613 557 557
Mean systolic blood
pressure (mmHg)
138.4 −2.4 139.3 −2.0 −0.4
Mean HbA1c* 7.9 −0.51 7.7 −0.26 −0.24
Log total chol/HDL
† 1.5 −0.05 1.5 −0.03 −0.01
UKPDS 10-year risk
All patients 30.7% −2.6% 31.0% −0.8% −1.8%
Upper tercile UKPDS risk 52.7% −7.0% 55.3% −4.1% −2.9%
Lower tercile UKPDS risk 18.5% −0.1% 19.6% 0.8% −0.9%
Change difference (column 5) is obtained by subtracting column 4 from column 2. It represents the additional reduction after the intervention compared to
the change in the control group.
Upper tercile group contains 225 intervention patients and 174 controls.
Lower terciles group contains 388 intervention patients and 383 controls.
*HbA1c is the glycosylated hemoglobin.
†Log total chol/HDL is the log of the ratio of total serum cholesterol divided by the high-density lipoprotein level.
Table 3. Adjusted Risk Change Difference and Number Needed
to Treat
Adjusted
Risk
Change
Difference
95% Confidence
Interval
NNT*
UKPDS 10-year risk
All patients −2.1% (−3.7%, −0.5%) 48
Upper tercile UKPDS −4.1% (−7.1%, −1.0%) 24
Lower tercile UKPDS −1.0% (−2.4%, 0.5%) –
Results shown are the adjusted differences in the pre–post changes in
10-year risk of myocardial infarction, fatal myocardial infarction, and
sudden death between the intervention and control groups. Models
adjust for age, comorbidity, severity of diabetes, and site of care between
intervention and control groups.
*Estimatednumberneededtotreattoreducetheriskofonecardiovascular
disease event is derived from the 10-year adjusted risk change difference.
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T)], where T is the
duration of disease, d=1.078 gives the increase in risk for each
year of duration, and q is the product of terms of the form bi
raised to the xi power.
32 Each bi is taken from Table 3 of their
publication and was estimated from UKPDS data; age at
diagnosis in years, female, Afro-Caribbean ancestry, smoking
HbA1c, systolic blood pressure, and log (total cholesterol/
HDL). This formula is described in further detail in the
technical appendix for this manuscript. We compared changes
in the UKPDS risk score in the groups exposed to the
intervention to changes in the control sample.
The control site is needed to adjust for local variation and
secular trends. Because the control patients may differ in ways
affecting reductions in risk factors, we adjust for character-
istics that might affect the change in risk factors over the year.
The two observation periods were the 11-month preinterven-
tion period and the 11-month postintervention observation
period that followed a 3-month period beginning after the first
collaborative meeting to allow the sites to begin making
changes (Fig. 1). To calculate CVD risk in each period, we used
the latest levels of the intermediate outcomes recorded in the
medical record for HbA1c, cholesterol ratio, and the average of
the 3 most recent for the blood pressures. The study protocol
was approved by the Human Subjects Protection Committees
from RAND, UCLA, and all participating oganizations.
Study Population
We used the diabetes registries from participating sites to
identify patients. All patients with diabetes were approached
to consent except for those at 2 clinical sites that had over 400
patients from which 200 patients were randomly selected. We
identified 3,080 eligible patients. No data were collected on
patients who declined consent (806). Patients were excluded if
they were unable to consent because they died (12), were in a
nursing home (9), did not speak English or Spanish (26), could
not be found (198), or were too ill to consent (36). In addition,
patients were excluded if the medical record could not be found
(30) or if they said they did not have diabetes (28). This resulted
in 1,935 consenting participants with charts available for
review. (Fig. 2) The analysis of the combined cardiovascular risk
score excluded patients missing more than 1 of the 6 modifiable
component values (pre- and postcholesterol ratios, HbA1c, and
systolic blood pressure) needed to calculate the UKPDS risk
score. A full description of the exclusion criteria and calculation
of the risk score can be found in the technical appendix of this
manuscript.
Data Collection
We obtained age, sex, cholesterol, HbA1c, blood pressure,
medications, comorbid conditions, and additional values for
the UKPDS risk score from the medical record. We also
abstracted other chronic medical conditions needed to calcu-
late a modified Charlson score.
33 The modified Charlson score
does not include HIV and moderate/severe liver disease (not
collected in our sample) or diabetes. The comorbidity index
used in regressions was based on the number of conditions
where 0=0; 1–2=1; 3–4=2; and >5=3. We also abstracted
treatment regimen (insulin, oral diabetes medications, or diet-
controlled) from medical records during the preintervention
period to calculate a measure of disease severity. After
documentation of informed consent, charts were either re-
viewed at the site or deidentified charts were mailed to a central
location. Trained abstractors entered data into a computerized
tool, and completed records were sent to a central data
repository. Lead abstractors initially reviewed a 10% subsample
of the other abstractors’ record reviews to ensure quality and
assess reliability. Kappa scores at the level of diabetes-related
care measures ranged from 0.62 to 0.88.
Imputation
We multiply imputed missing values when one of four chart
review values required for calculating changes in the UKPDS
risk score was missing, specifically 44 pre- or postperiod
HbA1c values (2%) and 395 pre- or postperiod total cholesterol
or HDL values (17%). We also multiply imputed 163 smoking
status indicators (14%). We used the Markov Chain Monte
Carlo Method implemented in Proc MI in SAS, copyright (c)
2002–2003 by SAS Institute Inc., Cary, NC, USA. Estimated
coefficients and variances from different imputations were
combined using Proc MI analyzed in SAS. Only 26 systolic
blood pressure values (<1%) were missing, so we imputed them
with mean values.
Analyses
We performed bivariate tests of association between the
baseline characteristics of intervention and control groups.
We use a random intercept hierarchical regression model
(Proc Mixed in SAS) to simultaneously adjust for clustering of
observations within patients (pre and post) and patients Figure 2. Patient selection.
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gender, comorbid conditions, and treatment regimen (ordered
categorical indicator variables for diet-controlled, oral agents
only, oral and insulin use, and insulin alone) to estimate the
adjusted change in differences over time between participat-
ing and control site patients. The two observations for each
patient were coded with indicators for being in the first or
second collaborative, being in an intervention site, postperiod,
and a postperiod by intervention site interaction term. The
coefficient of the postperiod by intervention site interaction
term is the estimated adjusted difference in change over time
in UKPDS score for those in the intervention versus control
groups.
RESULTS
Baseline characteristics were similar for intervention and
control patients except that those in the intervention group
were significantly more likely to be enrolled in an HMO
(Table 1). Patients in the intervention group had higher
preintervention mean HbA1c levels at 7.9% compared to the
control group 7.7% (p=0.02) (Table 1). There were no signifi-
cant differences in mean systolic blood or baseline cholesterol
ratios. The baseline 10-year cardiovascular disease risk for the
intervention group at 30.7% was similar to the control group
risk at 31.0% (p=0.86).
After the intervention, both the intervention and control
groups had lower systolic blood pressures, total cholesterol to
HDL ratios, and HbA1c values (Table 2). The intervention
group had a reduction in 10-year cardiovascular disease risk
from 30.7% in the preintervention period to 28.1% in the
postperiod, whereas the control group’s risk was lowered from
31.0 to 30.2% (Table 2). The highest risk tercile in the
intervention group had a reduction in 10-year cardiovascular
disease risk from 52.7 to 45.7%, whereas the control group’s
risk was lowered from 55.3 to 51.2% (Table 2).
Our adjusted analysis found a significantly greater risk
reduction in the intervention group of −2.1% (95% CI −3.7%,
−0.5%) (Table 3). In our adjusted analysis, the postintervention
risk in the highest risk tercile was significantly lower by 4.1%
(95% CI −7.1%, −1.0%) in the intervention group as compared
to the control group (Table 3).
DISCUSSION
Our study shows that a collaborative intervention designed to
help organizations implement the CCM for diabetes is associ-
ated with improved risk for cardiovascular disease predicted
by the UKPDS risk score. These findings suggest that
collaborative interventions may lead to reduced cardiovascu-
lar disease in patients with diabetes. Based on the results of
recent efficacy trials for hypertension
34,35 and cholesterol
management,
36 a stronger focus on cholesterol control and
BP control in the CCM model could be associated with even
bigger improvements in CVD risk. Recent observations of an
independent association of HbA1c with cardiovascular disease
risk also support a potential benefit in collaboratives reducing
CVD risk.
38
Within a 1-year postobservation period, implementation of
the CCM model was associated with significantly greater
reductions in lipids and HbA1c than what was observed in
the control group. Although one should be cautious when
applying NNT calculations to nonrandomized trials, we note
that if the observed resulting risk reduction of 2.1% were
realized, there would be one fewer myocardial infarction, fatal
myocardial infarction, or episode of sudden death for every 48
patients with diabetes at an intervention site during the next
10 years. The risk reductions among the highest risk patients
would correspond to one less CVD event for every 24 high-risk
persons exposed to the intervention. The reduced cardiovas-
cular disease risk of 2.1% in the overall sample and 4.1% in
the highest risk tercile of persons with diabetes is comparable
to the 3.2% reduction of major coronary events over 5 years
from simvastatin use found in the Heart Protection Study’s
diabetes population.
36 However, the UKPDS risk engine was
developed in the UK in the late 1990s and may not fully apply
to US populations in the current time where there is a greater
focus on pharmacological therapy directed at reducing CVD
risk among persons with diabetes. As similar studies examine
other CCM interventions, we will gain a greater understanding
of which diseases and populations are best targeted for
collaborative interventions.
TheNationalInstitutesofHealthhascalledformorepragmatic
research aimed at bridging the gap between clinical knowledge,
effective practice, and improved health.
38,39 Our methods show
how a practical clinical trial can provide important information
aboutthepotentialimpactoforganizationalchangeonthehealth
of patients. This broadens our understanding of how to reduce
diabetes-related cardiovascular disease beyond the evidence
from randomized controlled trials with highly restrictive proto-
cols.
11,16 According to the National Committee for Quality
Assurance, patients with poor control of their HbA1c (>9.5)
decreased nationally from 44.9% in 1999 to 42.5% in 2000.
40
Such secular trends highlight the importance of having control
sites in any evaluation of health interventions.
Other studies of the CCM have shown effectiveness in
improving various process measures,
18,22,24 but the clinical
relevance of these measures is sometimes lost on provi-
ders.
41,42 Our use of a measure of cardiovascular risk as a
summary intermediate outcome provides useful information to
decision makers and clinicians on how organizational change
can affect the health of their practice. The UKPDS risk score
was convenient for our evaluation, and such point scores can
be useful for tracking progress and communicating cardiovas-
cular risk to patients with diabetes, many of whom have
inaccurate perceptions of their risk for cardiovascular dis-
ease.
43 Clinicians and noncommercial organizations can
download the program used to calculate patient risk, without
charge, from the Oxford Center for Diabetes, Endocrinology,
and Metabolism’s website http://www.dtu.ox.ac.uk/index.
html?maidoc=/riskengine/download.html.
The few other controlled trials to test the effectiveness of the
CCM have had mixed results.
23,25,27–29 Horbar showed a
benefit on neonatal intensive care, and Piatt’s trial showed
improved intermediate outcomes in patients with diabetes,
whereas Landon’s analysis of HIV care and Solberg’s study of
preventive services showed little improvement in processes
and outcomes of care for those exposed to the interven-
tion.
25,27–29 Our intervention was modest in many respects—
teams spent 3 weekends learning concepts and methods to
take back to their plans and practices, and then work them
into their organizations over the year. However, by focusing on
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tracking those outcomes, exposure to the intervention was
associated with improvements.
Our study depended on the cooperation of a heterogeneous
group of health plans and practices and therefore suffered from
some inherent limitations. Four of the 17 eligible sites did not
participate in our evaluation because of perceived administra-
tive burdens such as acquisition of informed consent.
44 Be-
cause the CCM intervention was not randomly allocated to sites
within organizations, our results could suffer from selection
bias if intervention sites were more motivated to make changes
to improve care than the controls. To assess whether this was
the case, the study conducted surveys of the staff participants
in the study and surprisingly, we found that attitudes toward
quality and overall assessments of staff attitudes were some-
what less favorable at intervention sites. Please refer to the
technical appendix for the overall study on the ICICE website
http://www.rand.org/publications/WR/WR269/ for a further
detailed description of these survey results. That organizations
as a whole volunteered to participate is not a problem for our
comparison but does limit external validity.
Because our control sites came from the same organization
as the intervention sites, they could have learned of and
implemented changes. However, if there was contamination,
then the real improvement in CVD risk reduction observed in
the intervention sites would have been greater than what we
have reported. Our results may not generalize to providers
and facilities without the institutional or financial support for
change. Although our study’s participating organizations had
to use their own resources to carry out any changes, other
studies of collaboratives have shown improvement in care
among community health centers, which typically have fewer
resources and more challenging populations than traditional
practices.
22,23,25 Our study’s patient population was roughly
90% non-Hispanic white and thus underrepresented the other
27% of patients with type-2 diabetes in the United States.
45
Future studies are needed to test these methods in settings
where more racially and ethnically representative patients
with diabetes receive their care.
We have shown that the introduction of the CCM using a
collaborative intervention for diabetes care is associated with
a reduction in cardiovascular disease risk in patients with
diabetes. Future testing and greater use of similar collabo-
rative efforts may aid in reducing the burden of cardiovas-
cular disease in patients with diabetes.
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APPENDIX
TECHNICAL APPENDIX
Derivation of Predicted Cardiovascular Disease
(CVD) Risk
Change in 10-year predicted risk of fatal myocardial
infarction, nonfatal myocardial infarction, or sudden
death was determined by the UKPDS risk engine (Isis
Innovation Ltd 2001©). The UKPDS risk engine formula
is based on the data from 4,540 U.K. prospective
diabetes study patients followed up for roughly 10 years
tracking the natural history of treated diabetes. This
equation is a diabetes-specific formula which estimates
the risk of new coronary heart disease events in people
with type-2 diabetes based on their mutable character-
istics of glycosylated hemoglobin, systolic blood pressure,
total cholesterol/HDL cholesterol ratio, smoking status,
and immutable characteristics of age, sex, race/ethnicity,
and time since diagnosis of diabetes as risk factors.
32
The exact formula is given in the UKPDS formula section
below.
Additional Exclusion Criteria
During our medical record review, patients were excluded
from the UKPDS analysis if more than one lab- or
examination-based component necessary to calculate the
UKPDS risk score was missing from the medical record in
either the preintervention period or the postintervention
period (577). Patients were excluded if there was no
evidence of diabetes (82), they were not in an assigned
intervention or control site (39), or were under 25 years old
(67). This resulted in 1,170 patients eligible for the risk
score calculation during the pre- and postintervention
periods. Eligible patients and characteristics of those ex-
cluded are shown in Figure 2. (Figure 2 of the manuscript)
Participants who agreed to be interviewed were given a
telephone survey, which included demographic data, such
as race, and information not reliably available from the
medical record, such as current smoking status and
duration of diabetes. Some 1,011 out of 1,170 eligible
patients whose charts were reviewed also completed the
telephone survey.
Subgroup Analysis
We also conducted a preplanned subgroup analysis to
examine if the intervention affected patients of higher or
lower baseline predicted cardiovascular disease risk differ-
ently. From a cost and quality of care perspective, patients
with higher baseline risk may stand to gain the most benefit
from an intervention and may subsequently be identified for
a more targeted effort. Therefore, we compared the impact of
the intervention on change in cardiovascular risk for those
in the upper tercile versus the lower two terciles in each
collaborative of predicted preintervention cardiovascular risk.
We repeated our multiple hierarchical regression analyses to
determine the impact of the intervention on these two
groups.
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The change in risk over time for those exposed to the CCM
model is driven by changes in the three mutable character-
istics (e.g., systolic blood pressure, HbA1c, and total choles-
terol/HDL cholesterol). As described in the text, if the
patient had 5 of the 6 values needed for the calculation of
UKPDS risk scores in the pre- and postperiods, we imputed
the sixth value. HbA1c and total cholesterol/HDL ratio were
imputed using the Markov Chain Monte Carlo MCMC
method of Proc MI in SAS while we used the mean to
impute systolic blood pressure as less than 1% were
missing. Smoking status was also imputed using the MCMC
method of Proc MI in SAS. In addition to HbA1c, lipid
values, blood pressure values, and smoking, we also includ-
ed indicator variables for the site of care, gender, and age as
covariates. We compare the complete case results to the
multiply imputed results in Technical Appendix Table 1
below:
The nonmutable factors (e.g., race or age or duration,
which changes by 1 for all participants over the year) are
needed to determine the preintervention-predicted CVD risk
for the preplanned subgroup analysis, but these variables
have no direct effect on changes in risk over time. These and
one other risk engine variable, smoking status, were collected
from the patient survey. For the 159 patients who did not
complete the survey, we obtained age and sex from the
medical record and imputed the smoking and duration of
diabetes (because the coefficients for age at diagnosis and for
duration are so similar in the UKPDS formula, the survey-
given date of diagnosis used to compute duration has little
effect on risk). For purposes of calculating the UKPDS risk
score, missing smoking status was also imputed using
multiple imputation methods.
Because of the possibility that groups differing in race,
education, income, living alone, and insurance status might
respond differently to the intervention, we tested whether
changes in the UKPDS were influenced by those factors. We
performed sensitivity analyses on patients with complete
survey data comparing the changes in outcomes adjusted for
all these survey-based variables, with changes in outcomes
not adjusted for survey-based variables. There was no differ-
ence in the difference of changes in predicted risk in the
intervention versus control sites. In our final models that
generated the results in the paper, these survey-based vari-
ables were not included.
The UKPDS Formula
The risk of getting heart disease in the next year=1−[exp
(−qd
T)], where T is the duration of disease, d=1.078 gives the
increase in risk for each year of duration, and q is the product
of terms of the form bi raised to the xi power. Each bi is taken
from Table 3 and the appendix of their publication and was
estimated from UKPDS data. A coefficient greater than 1
implies additional risk for increases in the factor.
If risk factors had stayed the same in the study, risk would
have risen by a little less than 1.078 over the year simply
because of the increase in duration. To get to the 10-year risk, T
is replaced by T+1, T+2 ...fs T+9 in the formula, and the
resulting 10-year risk is 1–10-year survival, or 1   exp
 qdT 1 þ d þ d2 þ ...d9 ½  ðÞ .
Description of Clinical Sites
Because sites came from within the same organization, we
were able to match intervention and control sites on region,
type of clinical practice, and roughly on size. Differences
across overall organizations and their respective pairs are
shown below.
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Technical Appendix Table 1. Comparison of Multiple Imputation
Results to Complete Case Results
Multiple Imputation Results Complete Case Results
UKPDS
10-Year
Risk
Adjusted
Difference in
Changes
95%
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